Frankfurt/Munich, July 23, 2021 – McDermott Will & Emery advised STADA Arzneimittel AG on a license agreement to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN). The cooperation extends to the European Economic Area, Switzerland and the United Kingdom. It has a total value of EUR 97.5 million ($ 115 million) plus royalties.
STADA relies on a three-pillar strategy consisting of generics, specialty pharmaceuticals and non-prescription consumer healthcare products. STADA sells products in about 120 countries worldwide. Calliditas is a Nasdaq-listed clinical-stage pharmaceutical company based in Sweden and focusing on the development of orphan drugs.
The McDermott team advising STADA was led by Deniz Tschammler (Commercial/Regulatory, Munich) and Monika Richter (Life Sciences/Licensing, Frankfurt) and worked very closely with STADA’s inhouse team which comprised Christoph C. Dengler (EVP Global Legal / General Counsel), Marcus Heppner (Director Legal Affairs – Global BD&L and M&A) and Friederike Bockmann (Senior Legal Counsel).
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective — and often unexpected — solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.